Summary: Cryopreservation of immature or mature dendritic cells (DC) has been proposed as a suitable method to gain large numbers of DC for immunotherapeutic trials against cancer. However, clinical studies using cryopreserved DC have demonstrated only limited success so far. The aim of this study was to investigate whether cryopreservation of monocytes elicits more potent DC and whether these DC are comparable to freshly generated DC preparations. Monocytes, either separated immunomagnetically or by means of leukapheresis and elutriation, were differentiated into DC and cryopreserved at various developmental stages. DC preparations were analyzed regarding recovery, viability, phenotype, and functional properties. In contrast to DC frozen at their immature or semi-mature state, generation of DC from cryopreserved monocytes elicited viability values comparable with freshly generated DC. Furthermore, using frozen monocytes for DC differentiation revealed improved expression of DC surface markers and interleukin-12p70 secretion as compared with DC generated from frozen immature or frozen semi-mature DC. Impaired phenotypical appearance of the latter DC variants was further substantiated by functional analysis. T-cells cocultured with these DC showed decreased expression of interferon-g and granzyme B, and lowered proliferation when compared with T-cells cocultured with DC generated from frozen monocytes or DC generated from freshly isolated monocytes. Induction of regulatory T-cell populations was negligible among all investigated DC preparations. These findings may further improve DC-based immunotherapeutical protocols. Cryopreservation of unchallenged monocytes enables targeted therapy by loading DC with varying antigenic compositions in case of tumor escape during treatment.
I n the last decade, dendritic cell (DC)-based immunotherapy of malignant diseases gained vast attention. The unique capacity of DC to take up and process antigens and to present antigenic epitopes to CD4 + and CD8 + T-cells in combination with major histocompatibility and costimulatory molecules makes them ideal candidates for an immunotherapeutic approach. 1, 2 In the tumor microenvironment, the presence of factors such as interleukin-10 (IL-10), IL-6, transforming growth factor b, prostaglandin E 2 , gangliosides, and vascular endothelial growth factor may impair the function of DC and T-cells thus supporting progressive tumor growth. 1, 3, 4 Vaccination with ex vivo manipulated DC against cancer may circumvent these conditions and should be able to break immune tolerance by inducing tumor specific effector and memory T-cells, which could reduce tumor mass and control tumor relapse. 5, 6 Great efforts have been undertaken concerning DC-based immunotherapy of cancer. Promising outcomes could be achieved in mouse models. 7, 8 Clinical trials in humans have been reported for various malignancies including renal cell carcinoma, 9 prostate cancer, 10 melanoma, 11 B-cell lymphoma, 12 colorectal cancer, 13 non-small-cell lung carcinoma, 14 medullary thyroid carcinoma (MTC), 15 pancreatic carcinoma, 16 hepatocellular, and cholangiocellular carcinoma. 17 Although tumor specific immune responses have been frequently observed, most clinical studies did not elicit durable clinical responses in human cancer. [18] [19] [20] DC for ex vivo manipulation may be isolated directly from blood or derived from CD34 + progenitor cells. However, the most commonly used cell type for DC generation is the peripheral blood monocyte. 18 By treating monocytes with granulocyte macrophage-colony stimulating factor and IL-4; they can be easily differentiated into immature dendritic cells (imDCs). [21] [22] [23] Multiple monocyte isolation procedures have been described including adherence of monocytes to plastic substrates, immunomagnetic enrichment or density gradient centrifugation. Our group has repeatedly used positive immunomagnetic enrichment in clinical and experimental settings. 15, 24, 25 Although immunomagnetic isolation procedures fulfilling good manufacturing practice-criteria exist, concerns have been addressed regarding the activation of monocytes during isolation procedures or usage of xenogenic antibodies for separation. 18, 26, 27 Recently, monocyte elutriation, on the basis of counter-flow centrifugation, has been introduced as a fast and cost-effective method to isolate monocytes from leukapheresis products with satisfying purities using a closed system. 28 DC, generated from elutriated monocytes, are comparable with DC from plastic-adherent monocytes. 29 To the best of our knowledge, the question whether immunomagnetically isolated monocytes and elutriated monocytes yield comparable preparations of DC has not been addressed so far.
Leukapheresis and further elutriation offer the advantage of obtaining large amounts of monocytes upon a single venipuncture. From this starting population, a bulk of DC sufficient for a whole series of vaccination can be subsequently manufactured. Furthermore, using a single batch of DC with comprehensive determination of recovery, viability, phenotype, function, and sterility circumvents variations of DC properties generated from repeated blood collections. Such large-scale generation of DC for immunotherapeutic interventions requires cryopreservation until further use. Various reports have addressed the question whether cryopreservation of imDC or mature DC (mDC) affects their properties. Most authors found that freezing and thawing procedures are safe, do not alter DC function and phenotype and lead to a DC population comparable with freshly prepared DC. [30] [31] [32] [33] On the basis of these findings, several clinical DC immunotherapy studies were performed with DC, which were previously cryopreserved. [34] [35] [36] [37] [38] Given the fact that these studies elicited only limited clinical benefit, we questioned whether cryopreservation of differentiated DC indeed represents an optimal preparation technique.
In this study, we investigated whether DC generated from elutriated monocytes are comparable with DC generated from immunomagnetically isolated monocytes. Furthermore, we addressed whether cryopreservation of freshly isolated monocytes elicits DC superior to DC cryopreserved at their immature or mature state and whether such cryopreserved monocytes are equal in their capacity to differentiate into fully mature DC (fmDC) when compared with monocytes used freshly for DC generation. The resulting preparations of DC were compared in terms of recovery, viability, phenotype, and functional properties.
MATERIALS AND METHODS

Tumor Cell Lines
The MTC cell line SHER-I (kindly provided by Prof R. Pfragner, Department of Pathophysiology, Medical University of Graz) was cultured in D-MEM/F12 medium (1:1) +L-glutamine (Gibco, Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco) and 50 mg/mL gentamycin (Gibco) in a 5% CO 2 humidified atmosphere at 371C. Before preparation of the lysate SHER-I cells were extensively washed and cultured again in D-MEM/F12 medium (1:1) but without supplementation of FBS for 48 hours.
Preparation of Tumor Cell Lysate
SHER-I tumor cells were harvested, washed, and dissolved in aqua bidestillata (Fresenius Kabi, Graz, Austria) at a concentration of 80 to 100 Â 10 6 cells/mL. Five freeze (liquid nitrogen) and thaw (371C waterbath) cycles were used to obtain crude tumor lysate. The protein content was determined according to Bradford (Coomassie Plus Bradford Assay, Pierce, Rockford, IL). The tumor cell lysate was adjusted to a concentration of 2 mg/mL with RPMI 1640 medium+L-glutamine (Gibco) and stored at À 801C until use.
Patients
Apheresis products for monocyte elutriation and whole blood for preparation of peripheral blood mononuclear cells (PBMCs) and further immunomagnetic separation of CD14 + or CD3 + cells were obtained from 3 metastatic MTC patients. These patients were undergoing a phase-I DC-based immunotherapy trial as previously described. 15 Blood collection procedures were performed twice after written, informed consent. From each patient, first an apheresis product for monocyte elutriation and 2 to 3 weeks later whole blood for preparation of PBMC and for further immunomagnetic separation of CD14 + or CD3 + cells were collected.
Leukapheresis and Elutriation of Monocytes
Patients underwent monocyte separation using the fixed combination of the Cobe Spectra Auto PBSC apheresis device followed by counterflow elutriation using the Gambro Eltra system (both devices by Gambro BTC, Lakewood, CA). PBMC collection was performed as largevolume leukapheresis consisting of a minimum of 2.5 fold of the patient's total blood volume. To avoid citrate reactions all patients received a continuous infusion of 8.92 mM calcium (375.5 mg, diluted in 500 mL of saline), as described previously. 39 Counterflow elutriation was performed according to a standard protocol within 2 hours after completion of the PBMC apheresis collection. 40 As elutriation buffer, we used a 1% albumin/0.9% NaCl solution instead of the 1% albumin/ Hanks balanced salt solution as recommended by the manufacturer. In brief, after priming the leukapheresis product was loaded into the evenly rotating elutriation chamber. In a semi-automated mode the cells were separated in 5 fractions, each specified by the centrifugation speed, elutriation buffer flow rate, and process volume. The monocyte-enriched fraction (fraction 5) was collected in the rotor-off mode and directly collected into the final collection bag.
Preparation of PBMC and Immunomagnetic Isolation of CD14 + Cells and CD3 + T-cells
First, PBMC were isolated from EDTA-treated whole blood using Ficoll-Paque Plus (GE Healthcare, Uppsala, Sweden) density gradient centrifugation. CD14 + cells were further purified using a magnetic bead-conjugated mouse anti-human CD14 monoclonal antibody (CD14 MicroBeads, Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's protocol. CD3 + T-cells were isolated by CD3 positive selection from PBMC using a magnetic bead-conjugated mouse anti-human CD3 antibody (CD3 MicroBeads, Miltenyi Biotec) according to the manufacturer's protocol. The purity of isolated T-cells was consistently >95%. For both types of immunomagnetic selection, the Midi-MACS magnet in combination with an LS column was applied (both items by Miltenyi Biotec).
tumor cell lysate (generated from SHER-I tumor cells) in a 5% CO 2 humidified atmosphere at 371C. Monocytes were cultured at a concentration of 1 Â 10 6 cells per milliliter medium in an appropriate well size (Corning, Corning, NY). On day 2, half of the volume of growth medium containing freshly added cytokines (for the entire volume) was added. On day 3, imDC were subjected to maturation with 1mg/ml tumor necrosis factor-alpha (TNF-a, kindly made available by Dr HR. Alexander Jr, National Cancer Institute, Bethesda, MD), 1000 U/mL interferon-gamma (IFN-g, Imukin, Boehringer Ingelheim, Vienna, Austria), and 50 ng/mL lipopolysaccharide (LPS, Sigma Aldrich, St. Louis, MO). For phenotype determination, cells were matured with TNF-a, IFN-g, and LPS for 24 hours, whereas LPS had been added only for the last 4 hours of maturation for coculture assays to avoid loss of accumulated IL-12p70. DCs were harvested on day 3 (imDC) or day 4 (mDC) by gentle scraping and washing for phenotypical or functional analysis.
Nomenclature of Various DC Preparations
DC generated from immunomagnetically isolated monocytes will be further termed as ''DC from CD14 + isolated monocytes.'' DC resulting from elutriated monocytes without any intervening cryopreservation steps are indicated as ''DC from elutriated fresh monocytes.'' DC generated from elutriated and frozen/thawed monocytes, are designated as ''DC from elutriated frozen monocytes.'' Finally, DC generated from frozen/thawed immature DC, frozen/thawed semi-mature DC (smDC) or frozen/thawed fmDC (all originating from elutriated monocytes without any intervening cryopreservation step) are called ''DC from frozen imDC,'' ''DC from frozen smDC'' or ''DC from frozen fmDC,'' respectively. The schedule for generation of each DC preparation is indicated in Figure 1 . Before cryopreservation, ''DC from frozen smDC'' were matured with TNF-a and IFN-g but without LPS to avoid loss of accumulated IL-12p70. After thawing, cells were subjected to final maturation with LPS. In contrast, ''DC from frozen fmDC'' were subjected to cryopreservation after a full maturation with TNF-a, IFN-g, and LPS.
Cryopreservation and Thawing Conditions of Monocytes, imDC, smDC, and fmDC Aliquots of fresh monocytes, isolated by means of apheresis and elutriation, imDC, smDC, and fmDC (all generated from monocytes purified by apheresis and elutriation) were subjected to cryopreservation in freezing medium consisting of 70% RPMI 1640+L-glutamine, 20% autologous serum and 10% dimethyl sulfoxide (DMSO, Sigma). After resuspending the cells in freezing medium at a concentration of 1 Â 10 7 /mL, they were immediately transferred into 2 mL cryopreservation tubes (Simport, Beloeil, Canada) and slowly frozen at a cooling rate of À 11C/min to À 801C by using a freezing container (Nalgene, Rochester, NY). After storage of 16 hours at À 801C, samples were transferred into a liquid nitrogen container until use. For further investigation, frozen cells were allowed to thaw at room temperature for 10 min and retrieved from the cryopreservation tubes by rinsing with prewarmed (371C) RPMI 1640 medium+L-glutamine. Before use, cells were washed once with a 20-fold amount of RPMI 1640+L-glutamine to remove DMSO and autologous serum. Thawed cells were cultured under the same conditions as stated above. Where indicated, cells were alternatively cryopreserved in a mixture of 90% autologous serum and 10% DMSO and/or subjected to a rapid thaw in a waterbath at 371C, resulting in 4 different DC preparations: (1) cryopreservation with 20% autologous serum, thawing at room temperature, (2) cryopreservation with 20% autologous serum, thawing at 371C, (3) cryopreservation with 90% autologous serum, thawing at room temperature, and (4) 
IL-12p70 Assessment
The presence of IL-12p70 in the supernatants of DC cultures was evaluated using a commercially available kit (Human IL-12p70 ELISA, Bender MedSystems, Vienna, Austria) according to the manufacturer's protocol. Production of IL-12p70 is reported in pg/mL per 1 Â 10 6 cells. 
Carboxyflourescein Diacetate N-succinimidyl Ester Proliferation Assay
For carboxyflourescein diacetate N-succinimidyl ester (CFSE) proliferation assays, freshly isolated CD3 + T-cells were stained with CFSE (Fluka, Buchs, Switzerland) in D-PBS (Gibco) containing 0.1% bovine serum albumine (BSA, Sigma Aldrich) for 10 min at room temperature. Excess CFSE was removed by washing the cells with cold RPMI 1640 medium+L-glutamine supplemented with 10% FBS (HyClone) and 50 mg/mL gentamycin for 4 times. 5 cells were stained with the following mouse anti-human mAb: PE-labeled anti-CD3 antibody (Immunotech), EcD-labeled anti-CD4 antibody, Pc5-labeled anti-CD8 antibody, PE-labeled anti-IFN-g antibody, PE-labeled anti-IL4 antibody, PE-labeled anti-IL10 antibody, PE-labeled antigranzyme-B antibody (Serotec, Kidlington, UK) and PE-labeled anti-perforin antibody (Becton Dickinson). FITC/PE-labeled IgG1/IgG1 antibody, PE-labeled IgG2b antibody, EcD-labeled IgG1 antibody and Pc5-labeled IgG1 antibody served as isotype controls. Samples were analyzed in a Cytomics FC 500 flow cytometer using CXP Software. Fifty thousand events were acquired for each sample and the percentages of positively stained cells or cells, which had or had not undergone cell division, were reported. 
Assessment of Induction of Regulatory T-cells
RESULTS
Recovery, Viability, and Morphology of DC
First, the influence of various DC preparation techniques on recovery, viability, and morphology was assessed. As indicated in Figure 2A , all DC preparations showed comparable recovery rates at their immature state on day 3 (range: 48.2% to 58.3%). After maturation with TNF-a, IFN-g and LPS on day 4, recovery ranged from 22.2% to 28.5%, with the exception of mDC from frozen smDC (2.6%). Concerning viability, comparable values were found for all preparations of imDC (range: 92.6% to 96.1%, Fig. 2B ). Viability of DC from CD14 + isolated monocytes, elutriated fresh monocytes and elutriated frozen monocytes only dropped slightly after maturation (87.7%, 85.5%, and 87.5%, respectively), whereas mDC from frozen imDC (56.2%) and mDC from frozen smDC (21.5%) exhibited severely impaired viability values.
Similar results were obtained when the morphology of mDC from various preparations was observed. Mature DC from CD14 + isolated monocytes, mDC from elutriated fresh monocytes and mDC from elutriated frozen monocytes showed typical DC morphology (Figs. 3A-C), with a strong tendency to form large clusters. Clustering of mDC from frozen imDC (Fig. 3D ) and mDC from frozen smDC (Fig. 3E) was limited, resembling the morphology of imDC (Fig. 3F) .
These findings indicate that DCs generated from elutriated monocytes are fully comparable with DC from CD14 + isolated monocytes concerning recovery, viability, and morphology. Furthermore, imDC and smDC seem to be more vulnerable to freezing and thawing procedures than freshly isolated monocytes with respect to these parameters.
Phenotypical Appearance of DCs
Using flow cytometry, we subsequently determined the phenotypical appearance of imDC and mDC resulting from various DC preparation techniques. Table 1 demonstrates the phenotype of mDC after 24 hours of stimulation with TNF-a, IFN-g, and LPS. Expression of costimulatory molecules (CD40, CD80, CD86), antigen-presentation structures (CD1a, HLA-ABC, and HLA-DR), monocyte markers (CD14) and DC maturation markers (CD83) was evaluated regarding both, the percentages of positive cells (Table 1A ) and the MFI (Table 1B) . This representative experiment clearly shows that freezing and thawing of imDC or smDC has a negative impact on the expression of the investigated DC surface markers. In contrast to mDC from CD14 + isolated monocytes and mDC from elutriated fresh monocytes, these DC preparations elicited reduced percentages of positive cells especially concerning CD40, CD80, and CD83. These reductions were accompanied by low MFIs. For HLA-ABC and HLA-DR, no differences were seen regarding the percentages of positive cells, whereas mDC from frozen imDC or mDC from frozen smDC again elicited low MFI values. Expression of CD14 was low for all DC preparations. In contrast to DC from frozen imDC or DC from frozen smDC, freezing and thawing did not influence the percental expression of surface markers on mDC from elutriated frozen monocytes, with an even enhanced expression of CD1a. MFI values of some markers (CD40, CD83, and HLA-DR) were diminished when compared with mDC from CD14 + isolated monocytes. This is true for mDC from elutriated fresh monocytes as well, but their reduction was not as severe as for mDC from frozen imDC or mDC from frozen smDC. Figure 4 demonstrates the percental expression of CD40, CD80, and CD83 on imDC (day 3) and mDC (day 4) of all investigated DC preparations. In contrast to DC from elutriated frozen monocytes, which behaved like DC from CD14 + isolated monocytes or DC from elutriated fresh monocytes, freezing and thawing procedures had a severely negative impact on the maturation of DC from frozen imDC and DC from frozen smDC.
Furthermore, contamination of various preparations of mDC with T-cells (CD3), B-cells (CD19), NK-cells (CD56), and granulocytes (CD15) was assessed. As indicated in Table 2A , contamination of all DC preparations FIGURE 2. Recovery and viability of various DC preparations. Recovery and viability of various DC preparations was determined on day 3 at their immature state (imDC) and after maturation with tumor necrosis factor-a, interferon-g, and lipopolysaccharide on day 4 (mDC). One representative experiment of 3 is shown. A, Recovery (expressed as percent cells harvested from originally applied monocytes). B, Viability (assessed by means of trypan blue exclusion). DC indicates dendritic cell; imDC, immature dendritic cell; mDC, mature dendritic cell.
was low, mostly originating from B-cells and granulocytes. This confirms that low contents of CD83 + DC among mDC from frozen imDC and mDC from frozen smDC are not due to enhanced impurities, thus supporting the view that these DC preparations are impaired in their capacity to differentiate into fmDC. When tracing back contaminations to monocyte isolation procedures, one can recognize a somewhat more pure monocyte population after + isolated monocytes (A), mDC from elutriated fresh monocytes (B), mDC from elutriated frozen monocytes (C), mDC from frozen imDC (D), mDC from frozen smDC (E), and imDC from CD14 + isolated monocytes (F). Magnification: 100 Â . DC indicates dendritic cell; imDC, immature dendritic cell; mDC, mature dendritic cell; smDC, semimature dendritic cell. immunomagnetic CD14 + isolation than after elutriation (Table 2B) . Indeed, purity of CD14 + isolated monocytes ranged from 90.2% to 96.3%, whereas after elutriation cell preparations contained 84.3% to 87.5% monocytes (data not shown).
Assessment of IL-12p70 Production
As IL-12p70 is a potent promoter of T H 1 type immune responses (which include the activation of cytotoxic T lymphocytes), 41 IL-12p70 secretion of various DC preparations was assessed by measuring cytokine levels with a standard enzyme-linked immunosorbent assay. As demonstrated in Figure 5 , mDC from CD14 + isolated monocytes and mDC from elutriated fresh monocytes expressed the highest IL-12p70 levels (12016 pg/mL and 11084 pg/mL, respectively). In contrast, comparatively low levels were detected in the supernatant of mDC from frozen imDC and mDC from frozen smDC (2913 pg/mL and 1069 pg/mL, respectively). Mature DC from elutriated frozen monocytes were found to express intermediate levels of IL-12p70 (6637 pg/mL). Immature cells of all investigated DC preparations did not produce IL-12p70.
These data suggest that freezing and thawing procedures have a negative impact on IL-12p70 production. Furthermore, imDC and smDC seem to be more vulnerable to cryopreservation than freshly isolated monocytes with respect to IL12p70 expression. Low recovery and viability values of mDC from frozen imDC and mDC from frozen smDC, as illustrated above, might be partly responsible for low IL-12p70 measurements.
Intracellular Cytokine Detection in CD3 + T-cells
Next, we determined the potential of various mDC preparations to stimulate T H 1 polarization (IFN-g production) Furthermore, quantitative differences in IFN-g production of T-cells could be observed. Mature DC from CD14 + isolated monocytes and mDC from elutriated frozen monocytes elicited comparable frequencies of IFN-g positive T-cells, whereas mDC from frozen imDC and mDC from frozen smDC were impaired in their capacity to stimulate IFN-g expression. As shown for IFN-g, expression of CD69, a marker of T-cell activation, was dependent on the DC preparation used for coculture. Lowest expression of CD69 was detected after stimulation with mDC from frozen imDC or mDC from frozen smDC. Expression of all investigated parameters was low or negligible in PBMC, which were not cocultured with DC.
In summary, all examined DC preparations favour T H 1 polarization above T H 2 polarization. Consistent with our findings concerning recovery, viability, morphology, cell surface marker expression, and IL-12p70 production, mDC from frozen imDC and mDC from frozen smDC are impaired in their capacity to stimulate IFN-g production and activation of T-cells.
CFSE Proliferation Assays
To further assess the influence of various DC preparation techniques on the stimulatory capacity of the resulting mDC, CFSE proliferation assays were performed. Donor T-cells were stained with CFSE and cocultured with various mDC preparations. Proliferation of CD3 + T-cells and their CD4 + and CD8 + subpopulations are demonstrated in Figure 7 . Mature DC from CD14 + isolated monocytes stimulated the highest proliferation rates. Comparable, although somewhat lower values were found for T-cells cocultured with mDC from elutriated frozen monocytes. Mature DC from frozen imDC and mDC from frozen smDC stimulated autologous T-cell proliferation only to a minor extent. No DC preparation elicited preferential proliferation of CD4 + or CD8 + T-cells. T-cells cultured without mDC showed no proliferative response. Simultaneously, CFSE-stained T-cells were assessed for expression of IFN-g, IL-4, and IL-10 (Table 3 ). In accordance with intracellular cytokine detection after 24 hours, IFN-g production after 96 hours was found to be highest in T-cells cocultured with mDC from CD14 + isolated monocytes and mDC from elutriated frozen monocytes. Again, mDC from frozen imDC and mDC from frozen smDC seemed to be impaired in their capacity to stimulate IFN-g production. Levels of IL-4 and IL-10 expression were low after 96 hours of coculture, again confirming a preferential shift to T H 1 immune responses.
Moreover, mDC of various preparations were investigated for their capacity to stimulate expression of perforin and granzyme B, mediators of cytotoxic T-cell responses, in CSFE-stained CD8 + T-cells. As shown in Figure 8 , highest granzyme B expression levels were detected in T-cells cocultured with mDC from CD14 + isolated monocytes or mDC from elutriated frozen monocytes. Granzyme B production of CD8 + T-cells was somewhat lower after coculture with mDC from frozen imDC and mDC from frozen smDC. Expression of perforin in CD8 + T-cells seemed to be independent of the type of DC preparation used for coculture. Similarly, no coherence between the percentages of divided cells within the granzyme B or perforin positive population and the DC preparation used for coculture could be revealed. Compared with CD8 + T-cells stimulated with DC, T-cells cultured without DC elicited low levels of granzyme B and perforin expression.
Assessment of Induction of Regulatory T-cells
Regulatory T-cells can be activated and expanded in vitro and upon therapeutic interventions with DC. Because of their ability to down-regulate anti-tumor T-cell responses they can arise as undesirable concomitants of DC vaccination procedures. [42] [43] [44] Among other subsets, the system of regulatory T-cells includes classical regulatory T-cells (CD4 + CD25 + FOXP3 + , T reg ) and IL-10 expressing inducible regulatory T-cells (CD4 + IL-10 + , T R 1). 3 Induction of regulatory T-cells by various DC preparations was assessed after 96 hours of coculture using flow cytometry. Figure 9A indicates the percentages of classical regulatory T-cells. Upon coculture with various mDC preparations, induction of T reg was imperceptible when compared with T-cells cultured without DC. Similarly, induction of T R 1 cells was negligible after coculture with various mDC preparations (Fig. 9B) .
Assessment of DC From Frozen fmDC
As many clinical DC immunotherapy studies have used cryopreserved fmDC for vaccination, we further wanted to assess these cells in comparison with the other DC preparations examined so far. Recovery and viability of various DC preparations including DC from frozen fmDC are illustrated in Figures 10A and B , respectively. Surprisingly, recovery and viability of DC from frozen fmDC were determined to be comparable with DC from CD14 + isolated monocytes, DC from elutriated fresh monocytes, DC from elutriated frozen monocytes and DC from frozen imDC. Similar to these findings, cell surface markers of mDC from frozen fmDC were comparable with DC from CD14 + isolated monocytes, DC from elutriated fresh monocytes and DC from elutriated frozen monocytes. Table 4A gives the percentages of positive cells; Table 4B lists the corresponding MFI values.
When mDC from frozen fmDC were investigated in terms of their capacity to secrete IL-12p70, we could reveal a striking ''exhausted'' functional status. Figure 10C depicts IL-12p70 production of various DC preparations. IL-12p70 secretion of mDC from frozen fmDC was low (491pg/ml) but comparable with mDC from frozen smDC (987pg/mL). As already shown in Figure 5 , highest levels of IL-12p70 were measured in supernatants of mDC from CD14 + isolated monocytes (26249 pg/mL), mDC from elutriated fresh monocytes (25256 pg/mL) and mDC from elutriated frozen monocytes (15402 pg/mL). We further assessed whether restimulation with LPS after thawing could force mDC from frozen fmDC into increased IL-12p70 secretion.
24 hours of restimulation of thawed mDC from frozen fmDC did not significantly increase production of this cytokine (451 pg/mL without LPS vs. 582 pg/mL with LPS restimulation), which obviously reflects their ''exhausted'' properties in terms of IL-12p70 production.
Next, we assessed the capacity of mDC from frozen fmDC to stimulate T-cell proliferation and perforin and granzyme B expression in CD8 + T-cells after 4 days of coculture. The corresponding results are given in Table 4C . FIGURE 10. Assessment of DC from frozen fmDC. A, Recovery of various DC preparations was determined on day 3 at their immature state (imDC) and after maturation with TNF-a, IFN-g, and LPS on day 4 (mDC). Recovery is expressed as percent cells harvested from originally applied monocytes. B, Viability of various DC preparations was determined on day 3 at their immature state (imDC) and after maturation with TNF-a IFN-g, and LPS on day 4 (mDC). Viability was assessed by means of trypan blue exclusion. C, IL-12p70 production of various DC preparations was assessed by enzyme-linked immunosorbent assay. Supernatants of immature DC (day 3, imDC) and after maturation with TNF-a, IFN-g, and LPS (day 4, mDC) were taken. IL-12p70 concentration is indicated as pg/mL per 1 Â 10 6 DC. DC indicates dendritic cell; fmDC, fully matured dendritic cell; IFN, interferon; IL, interleukin; imDC, immature dendritic cell; LPS, lipopolysaccharide; mDC, mature dendritic cell; TNF, tumor necrosis factor.
With the exception of perforin expression (which was similar to T-cells cultured without DC), mDC from frozen fmDC were functionally comparable with mDC from CD14 + monocytes, mDC from elutriated frozen monocytes, and mDC from frozen imDC.
Assessment of Various Cryopreservation and Thawing Procedures
One might argue that our procedure of thawing cells (10 min at room temperature) is against the general rule of thawing cells quickly (for example, in a waterbath at 371C) and-when compared to monocytes-is possibly effecting imDC, smDC, and fmDC negatively. Moreover, it is proposed to freeze DCs in pure human serum and 10% DMSO instead of 20% serum and 10% DMSO (as we did). 32 To investigate whether our protocol of cryopreservation and thawing favours monocytes and/or is more stressing to imDC, smDC, or fmDC, we additionally compared freezing of elutriated monocytes, imDC, smDC, and fmDC with 20% autologous serum or 90% autologous serum and their subsequent thawing at room temperature or at 371C. Figure 11 depicts recovery and viability of all investigated DC preparations. Differences between varying procedures of cryopreservation and thawing were moderate, indicating just a little or no effect on recovery or viability values.
Next, we assessed the influence of various techniques of cryopreservation and thawing on the expression of DC surface markers after 24 hours of stimulation with TNF-a, IFN-g, and LPS. Similar to our findings for recovery and viability, the impact of different cryopreservation/thawing procedures on the phenotypical appearance was moderate, with even minor advantages for cryopreservation with 20% autologous serum. Although the combination of cryopreservation with 90% autologous serum and thawing at 371C led to a moderate increase in CD40, CD80, and CD83 expression in mDC from frozen smDC, this procedure could not restore the phenotype to the degree observed for the other mDC preparations (data not shown).
Finally, we investigated the secretion of IL-12p70 with respect to different procedures of cryopreservation and thawing. Concerning this parameter, more differences are visible. Amounts of IL-12p70 secreted by various DC preparations (after 24 hours of stimulation with TNF-a, IFN-g, and LPS) are listed in Table 5 . When elutriated monocytes were subjected to cryopreservation with 90% autologous serum, IL-12p70 secretion of mDC was markedly reduced when compared with monocytes frozen in media containing 20% autologous serum. With regard to [A] DC of various preparations were harvested after maturation with TNF-a, IFN-g, and LPS, and stained with a panel of monoclonal antibodies as indicated. The percentage of positive cells for the analyzed molecule in relation to the appropriate isotype control is stated.
[B] DC of various preparations were harvested after maturation with TNF-a, IFN-g, and LPS, and stained with a panel of monoclonal antibodies as indicated. The MFI of the analyzed surface molecules is listed.
[C] Freshly isolated CD3 + T-cells were stained with carboxyflourescein diacetate N-succinimidyl ester and cocultured with mature autologous DC of various preparations. T-cells cultured without DC served as control. After 4 days of incubation, cells were stained and analyzed by flow cytometry. Proliferation rates of CD3 + , CD4 + , and CD8 + T-cells and CD8 + T-cells expressing perforin or granzyme B are listed. DC indicates dendritic cell; fmDC, fully mature dendritic cell; IFN, interferon; imDC, immature dendritic cell; LPS, lipopolysaccharide; mDC, mature dendritic cell; MFI, mean fluorescence intensity; smDC, semi mature dendritic cell; TNF, tumor necrosis factor.
DC from frozen imDC, this effect could be observed as well, but was less pronounced. Cryopreservation of smDC revealed highest IL-12p70 production when cells were frozen with 90% autologous serum and thawed at 371C, but the cytokine levels were rather low when compared with mDC from elutriated frozen monocytes. When fmDC were subjected to cryopreservation and thawed again, IL-12p70 secretion was low, regardless of the percentage of autologous serum or temperature while thawing.
DISCUSSION
In this study, we show that freshly isolated monocytes, either separated immunomagnetically with CD14 MicroBeads (resulting in DC from CD14 + isolated monocytes) or by means of leukapheresis and elutriation (resulting in DC from elutriated fresh monocytes), can be differentiated into DC, which are comparable concerning recovery, viability, morphology, percental expression of cell surface markers, and IL-12p70 production. Our findings extend the study by Berger et al, 29 demonstrating that monocyte elutriation is equal to monocyte adherence, another standard monocyte isolation procedure. Although purity of immunomagnetically isolated monocytes was found to be somewhat higher than of elutriated monocytes, percentages of cells expressing the DC maturation marker CD83 were equal in both preparations of terminally differentiated DC ( Table 2) .
Purity of matured DC is crucial, as these cells are injected or infused into patients upon DC-based immunotherapy trials. Our data prove that contamination with T-cells, B-cells, NK-cells and granulocytes is low in both preparations of mDC.
Monocyte yields after elutriation were assessed to be varying among the examined patients, ranging from 480 Â 10 6 to 2200 Â 10 6 cells (data not shown). Given a median recovery of mDC of 25%, 120 Â 10 6 to 550 Â 10 6 mDC can be harvested, which is sufficient for a complete vaccination series (when performing 10 vaccinations at 10 Â 10 6 mDC each). Thus, repeated venipuncture of patients undergoing DC-based immunotherapy can be circumvented by leukapheresis and monocyte elutriation. Isolation of a bulk of monocytes before starting DC vaccination bears another remarkable advantage. In contrast to most DC immunotherapy trials conducted so far, which had defined chemotherapy and radiotherapy as an exclusion criteria, a few studies have addressed the question of combining DC vaccination with such standard therapies. [45] [46] [47] As chemotherapy and radiotherapy may elicit bone marrow toxicities, one can ensure a defined and constant population of monocytes by performing leukapheresis and elutriation in advance.
Leukapheresis and further monocyte elutriation procedures bring about the problem of handling large cell amounts at the time of separation when compared with FIGURE 11 . Recovery and viability of DC generated with various cryopreservation/thawing techniques. Recovery and viability of various DC preparations was determined on day 3 at their immature state (imDC) and after maturation with TNF-a, IFN-g, and LPS on day 4 (mDC). Recovery is expressed as percent cells harvested from originally applied monocytes. Viability was assessed by means of trypan blue exclusion. DC generated with 4 different cryopreservation/thawing techniques are shown: (1) cryopreservation with 20% autologous serum, thawing at RT (20%, RT), (2) cryopreservation with 20% autologous serum, thawing at 371C (20%, 371C), (3) cryopreservation with 90% autologous serum, thawing at room temperature (90%, RT), and (4) cryopreservation with 90% autologous serum, thawing at 371C (90%). DC indicates dendritic cell; IFN, interferon; imDC, immature dendritic cell; LPS, lipopolysaccharide; mDC, mature dendritic cell; RT, room temperature; TNF, tumor necrosis factor.
repetitive blood collections. Several investigators solved this problem by cryopreserving imDC or mDC for vaccination. [34] [35] [36] [37] [38] As clinical benefit was limited in these studies, another aim of our investigations was to clarify whether cryopreservation of monocytes and batchwise generation of DC may be advantageous compared with freezing of already differentiated DC. Furthermore, we wanted to address the question whether such cryopreserved monocytes are equal in their capacity to differentiate into fmDC when compared with monocytes used freshly for DC generation. For this purpose, we compared DC derived from immunomagnetically isolated monocytes with DC generated from elutriated monocytes cryopreserved at their undifferentiated (monocyte) or more differentiated (imDC, smDC, or fmDC) state. This approach implies one limitation: due to the study design, DC from elutriated fresh monocytes (generated without any cryopreservation step) could not be simultaneously compared with DC from elutriated frozen monocytes and DC from imDC, DC from smDC, or DC from fmDC. Given the fact that immunomagnetically separated monocytes yield DC equal to DC derived from elutriated fresh monocytes (as discussed above), we were able to compare DC derived from immunomagnetically isolated monocytes with various DC preparations generated from elutriated monocytes including one step of cryopreservation.
Our data indicate that DC differentiated from cryopreserved monocytes display features similar to DC generated from monocytes immediately after their separation. These DC preparations were found to be comparable with respect to recovery and viability rates, morphology and expression of cell surface markers. IL-12p70 levels in DC supernatants were assessed to be lower when monocytes had been frozen subsequent to separation (Fig. 5) . Nevertheless, IL-12p70 production of this DC preparation was high when compared with other reports 48, 49 and sufficient to induce equivalent frequencies of IFN-g positive T-cells after 24 hours and 96 hours of coculture (Fig. 6,  Table 3 ). Our findings can be related to a report describing that IL-12 secretion is diminished in preparations of frozen PBMC compared with fresh PBMC upon stimulation with LPS. 50 As monocytes were identified as the main source of IL-12 and IL-10 was assessed to be a major inhibitor of IL-12 production, 51 it is possible that enhanced secretion of IL-10 of cryopreserved monocytes (and/or differentiated DC) is responsible for the decreased IL-12p70 expression of mDC from elutriated frozen DC in our setting. Lowered IL-12p70 levels of DC generated from cryopreserved monocytes might be responsible for a somewhat reduced rate of overall T-cell proliferation (Fig. 7) .
When DC were frozen at their immature or semimature state, resulting preparations of mDC were assessed to be impaired concerning recovery, viability, morphology, expression of cell surface markers, and IL-12p70 production when compared with mDC derived from elutriated frozen monocytes. Diminished performance of mDC from frozen imDC and mDC from frozen smDC can be directly linked to cryopreservation of these already differentiated cell preparations as cryopreservation affected monocytes only to a minor extent (as discussed above) and all immature DC preparations displayed similar features before they were frozen. To a considerable extent, impaired phenotypical performance of mDC from frozen imDC and mDC from frozen smDC resulted in diminished functional properties. The capacity of mDC to stimulate expression of CD69, IFN-g, and granzyme B in cocultured T-cells was lowered when imDC or smDC were subjected to cryopreservation. Additionally, these mDC preparations elicited reduced T-cell proliferation rates when compared with mDC from elutriated frozen monocytes. Reduced functional properties of mDC from frozen imDC and mDC from frozen smDC were not due to activation and/or expansion of regulatory T-cells, as we failed to detect both, classical regulatory T-cells and inducible regulatory T-cells. Our findings are in contrast to previous studies confirming that cryopreservation of imDC or mDC does not affect DC phenotype or function when compared with DC generated immediately after monocyte isolation or subsequent to monocyte cryopreservation. [30] [31] [32] [33] We are well aware of the fact that different protocols may lead to DC preparations with different properties, but with regard to our mode of DC preparation, cryopreservation at the stage of monocytes rather than imDC or smDC is clearly favorable. Additionally, we have investigated the properties of mDC generated from frozen fmDC. Surprisingly, recovery, viability, expression of cell surface markers, and discrete functional properties (for example T-cell proliferation) were found to be similar to DC generated from elutriated frozen monocytes. However, with respect to their ability to secrete IL-12p70 they proved to display a so-called ''exhausted'' phenotype.
52,53 IL-12p70 secretion by mDC from frozen IL-12p70 production of mDC generated with various cryopreservation/ thawing techniques was assessed by enzyme-linked immunosorbent assay. Supernatants of mDC after 24 hours of maturation with tumor necrosis factor-a, interferon-g, and lipopolysaccharide were taken. IL-12p70 concentration is indicated as pg/mL per 1 Â 106 DC. DC generated with 4 different cryopreservation/thawing techniques are shown: (1) cryopreservation with 20% autologous serum, thawing at RT (20%, RT), (2) cryopreservation with 20% autologous serum, thawing at 371C (20%, 371C), (3) cryopreservation with 90% autologous serum, thawing at RT (90%, RT), and (4) cryopreservation with 90% autologous serum, thawing at 371C (90%, 371C).
DC indicates dendritic cell; fmDC, fully matured cell; IL, interleukin; imDC, immature dendritic cell; mDC, mature dendritic cell; RT, room temperature; smDC, semi mature dendritic cell. fmDC after thawing was low (reaching only 2.9% of IL12p70 amounts of mDC from elutriated frozen monocytes) and could not be enhanced significantly even after a 24 hours restimulation period with LPS. Prior studies dealing with cryopreservation of DCs for immunotherapy trials have not addressed the question of IL-12p70 secretion after thawing of frozen fmDC. IL-12p70 secretion of DC favors triggering T H 1-type immune responses and antitumour activity of CD8 + T-cells has been proven to be enhanced by IL-12p70. 54 Using ''exhausted'' DC such as mDC from frozen fmDC may therefore display a considerable drawback in clinical DC immunotherapy trials. Moreover, when using mDC from frozen fmDC it is not possible to switch the antigen composition for DC loading if necessary. This might be important with respect to tumor escape variants, which will be discussed below.
We further determined the effect of different cryopreservation and thawing techniques on the properties of various DC preparations. The influence of the temperature during the thawing process (which includes the rapidness of thawing) seems to be of less importance than assumed. Thawing of cells for 10 minutes at room temperature has no measurable negative effect when compared with a quick thawing at 371C (which takes about 2 to 3 min). However, with regard to our findings concerning IL-12p70 production, freezing of cells (monocytes) with 20% autologous serum is favourable to cryopreservation with 90% autologous serum. Enhanced IL-12p70 secretion by mDC from elutriated monocytes cryopreserved with 20% autologous serum may contribute to their improved functional performance and supports our cryopreservation approach. Conversely, cryopreservation of imDC or smDC with 90% autologous serum does not lead to a significant improvement of their performance. Furthermore, cryopreservation of monocytes with 20% serum requires collection of less serum, which is a clear advantage for patients. For example, freezing of 1000 Â 10 6 elutriated monocytes (at a density of 10 Â 10 6 cells/mL) requires 20 mL of autologous serum (for freezing in 20% serum), whereas cryopreservation in pure serum and 10% DMSO would require 90 mL of autologous serum (which would implicate the collection of at least 200 mL of peripheral blood).
In addition to qualitative advantages, cryopreservation of freshly isolated monocytes bears a great logistic benefit. It is well known that malignant cells can gain resistance to treatment by various mechanisms. [55] [56] [57] [58] Furthermore, tumor escape variants often display altered antigen expression patterns. [59] [60] [61] An ideal DC-based immunotherapy would target such altered tumor cells prone to escape immune surveillance. This treatment modality therefore requires challenging DC with different antigen compositions in the course of time, individually dependent of the (altered) expression of antigens by malignant cells. As imDC or mDC subjected to cryopreservation are already loaded with antigen, freezing of untreated monocytes facilitates this targeted treatment approach.
Furthermore, our protocol for monocyte isolation, cryopreservation, and subsequent DC differentiation can be easily adapted to current good manufacturing practice guidelines. More recently, we have succeeded in cultivation of the tumor cell line SHER-I under FBS-free conditions, thereby being able to generate mDC without addition of any xenogenic proteins (data not shown).
Taken together, we could prove that (1) immunomagnetically separated monocytes and elutriated monocytes yield comparable preparations of mDC, that (2) the properties of DC derived from cryopreserved monocytes are equal to the features displayed by DC generated from freshly isolated monocytes, and that (3) cryopreservation of differentiated DC (imDC, smDC, or fmDC) bears drawbacks when compared with cryopreservation of monocytes intended for DC generation. Our report clearly claims further studies to investigate the underlying mechanisms, which are responsible for the diminished phenotypical and functional capacities of DC generated from frozen imDC, frozen smDC and frozen fmDC. Finally, we demonstrate a method for obtaining a large quantity of functional DC for immunotherapeutical use in clinical protocols.
